Understand the source comparison
The Unvarnished Truth About NAD+ vs SS-31
Here's the honest answer: neither compound is a standalone solution for mitochondrial decline, and the 'which is better' framing misses the point. NAD+ precursors address one bottleneck (substrate depletion), SS-31 addresses a different bottleneck (membrane in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's the honest answer: neither compound is a standalone solution for mitochondrial decline, and the 'which is better' framing misses the point. NAD+ precursors address one bottleneck (substrate depletion), SS-31 addresses a different bottleneck (membrane instability), and aging mitochondria have both problems simultaneously. The most robust preclinical data comes from combination protocols. Using NAD+ to drive biogenesis and SS-31 to protect the newly generated mitochondria from immediate oxidative damage. Single-agent trials show modest, inconsistent benefits because they're only addressing half the pathology. The research community is moving toward multi-target mitochondrial cocktails, not single-compound interventions, because that's what the biology demands. If your research question involves severe, acute mitochondrial damage (ischemia, neurodegeneration, genetic disorders), SS-31 is the more evidence-backed starting point. If you're studying metabolic aging or early dysfunctio
- The current limitation is that SS-31 requires parenteral administration (it degrades in the GI tract), making it less practical for long-term oral supplementation studies compared to NAD+ precursors. Oral SS-31 formulations with improved bioavailability are in development but not yet available for research use. That practical constraint shapes protocol design more than the mechanistic science does. Researchers often choose NAD+ precursors by default because they're easier to administer, not because they're more effective.
- Our commitment to supporting cutting-edge mitochondrial research extends across our catalog. Researchers working on neuroprotection and cognitive enhancement protocols often explore compounds like Cerebrolysin and Dihexa, which address synaptic function and neuroplasticity. Mechanisms that intersect with mitochondrial bioenergetics in age-related cognitive decline. Every compound we supply undergoes rigorous third-party purity verification because mitochondrial research demands precision at the molecular level. When the science requires exact sequencing, contaminant-free synthesis, and consistent batch-to-batch reliability, that's the standard we've built Real Peptides around.
- The comparison between NAD+ and SS-31 isn't about finding a winner. It's about matching the mechanism to the mitochondrial pathology you're studying. If your model shows energy depletion without membrane damage, NAD+ precursors restore substrate availability. If the membranes are oxidized and cristae are disrupted, SS-31 stabilizes the architecture that NAD+ alone can't repair. Most aging and disease models require both, which is why combination protocols are becoming the standard in serious mitochondrial research. The decision isn't which is better. It's which bottleneck you're addressing first, and whether the biology demands one mechanism or both.